Today, the U.S. Department of Health and Human Services made its initial offers to pharmaceutical companies pursuant to the Biden Administration’s Inflation Reduction Act, which allows the U.S. Government to “negotiate” Medicare drug prices.
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2023 adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus of $2.28. Sales increased 7.3% Y/Y to $21.4 billion, beating the consensus of $20.99 billion, with operational growth of 7.2% and adjusted operational growth of 5.7%. Operational growth, excluding the COVID-19 Vaccine, was 10.9%. Pharmaceutical segment sales increased by 4.2% to $13.72 billion. Darzalex (cancer drug) and Stelara (Crohn’s disea
US Medicare price negotiations powerful move to rein in healthcare costs: Experts thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.